Thromboendarterectomy vs. Endovascular Therapy in Common Femoropopliteal Territory. Is Surgery Still the Gold Standard?

For lesions in the common femoral artery, guidelines recommend surgical endarterectomy (TEA) as the gold standard. However, endovascular therapy (EVT) is an alternative option for these lesions. 

Tromboendarterectomia vs terapia endovascular en territorio femoral común ¿Sigue siendo el ¨gold standard¨el tratamiento quirúrgico en este territorio?

In 2017 the first randomized study comparing TEA vs EVT was carried out, showing that EVT presents clinical benefits, though it does not replace surgical treatment as first treatment option in these cases. 

The aim of this multicenter retrospective study was to compare EVT vs TEA clinical outcomes in the treatment of the common femoral artery. 

Primary end point was loss of patency defined by doppler or ≥50% restenosis at 1-year followup. Secondary end point included periprocedural complications, hospitalization duration, endovascular reintervention, or surgery.  

The study looked at 1193 patients, 761 treated with EVT and 432 with TEA; mean age was 74, and they were mostly men. Smoking and diabetes were the most frequent risk factors. Half of EVT patients received balloon angioplasty and 23% stenting. The use of ultravascular ultrasound was 59%, and the TEA group presented more complex lesions, high Rutherford 5 percentage and sub-occlusive lesions. 

Read also: Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?

Primary end point at one year was higher among TEA patients (82.3% vs 96.6%; P < 0.001). Restenosis risk was more frequent in EVT outpatients. However, hospitalized patients presented lower risk of restenosis compared against outpatients (statistically non-significant). Intervention free rate was higher in the TEA group (89.2% vs 97.0%; P = 0.002). However, there were no differences in survival and limb salvage. Perioperative complications were more frequent among surgical patients and hospital stay was longer in this group. 

Conclusion

TEA showed efficacy and safety at one-year followup in this multicenter study, which is why this therapy continues to be the gold standard. Non-ambulatory patients might benefit from EVT. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial board of SOLACI.org.

Original Title: 1-Year Outcomes of Thromboendarterectomy vs Endovascular Therapy for Common Femoral Artery Lesions CAULIFLOWER Study Results.

Reference: Tatsuya Nakama, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...